SIBO Symptoms: What Could Be Causing Them and What to Do Next

What Is SIBO and How Does It Produce Symptoms?

SIBO develops when bacteria that normally reside in the colon migrate into or proliferate within the small intestine, where bacterial counts are typically low. The excess bacteria ferment carbohydrates before the host can absorb them, generating hydrogen, methane, or hydrogen sulfide gas. This fermentation drives the bloating and distension that most patients describe as their primary complaint.

The clinical definition has shifted over the past decade. The 2020 American College of Gastroenterology (ACG) Clinical Guideline, authored by Pimentel et al., lowered the diagnostic threshold for jejunal aspirate culture from 10⁵ colony-forming units per milliliter (CFU/mL) to 10³ CFU/mL, reflecting improved understanding of clinically significant overgrowth 1. This revision means that patients previously labeled "subclinical" may now meet criteria for treatment.

Beyond gas production, bacterial overgrowth damages the mucosal brush border of the small intestine. The result is impaired absorption of fats, fat-soluble vitamins (A, D, E, K), and vitamin B12 2. Patients with long-standing, untreated SIBO can develop measurable deficiencies. Iron and B12 deficiency anemia, osteomalacia from vitamin D malabsorption, and peripheral neuropathy are all documented downstream consequences.

Recognizing the Symptoms of SIBO

The symptom profile of SIBO overlaps heavily with irritable bowel syndrome (IBS) and functional dyspepsia, which is one reason it goes undiagnosed for months or years. Bloating ranks as the single most reported symptom, present in over 80% of SIBO-positive patients in a 2017 systematic review by Ghoshal et al. published in the Journal of Neurogastroenterology and Motility 3.

Typical symptoms include:

• Abdominal bloating and visible distension, often worsening after meals
• Excessive flatulence, driven by bacterial fermentation of unabsorbed carbohydrates
• Diarrhea, particularly with hydrogen-dominant overgrowth
• Constipation, more common in methane-dominant overgrowth (now termed intestinal methanogen overgrowth, or IMO)
• Abdominal cramping or pain, usually diffuse and postprandial
• Steatorrhea (pale, greasy stools), indicating fat malabsorption
• Unintentional weight loss in severe or chronic cases
• Fatigue and brain fog, potentially linked to systemic inflammation and nutrient depletion

The gas subtype matters clinically. A 2020 consensus statement from Rezaie et al. in the American Journal of Gastroenterology distinguished hydrogen-dominant SIBO (associated with diarrhea) from methane-dominant overgrowth (associated with constipation and slower intestinal transit) 4. Hydrogen sulfide-dominant SIBO, a more recently characterized variant, may present with diarrhea and sulfurous-smelling gas, though validated diagnostic criteria remain limited.

"The symptom overlap between SIBO and IBS-D is so substantial that some investigators have proposed SIBO as the underlying etiology in a meaningful subset of IBS patients," wrote Dr. Mark Pimentel of Cedars-Sinai in a 2019 editorial in Alimentary Pharmacology and Therapeutics 5.

What Causes SIBO? Risk Factors and Underlying Conditions

SIBO is not a primary disease. It is a consequence of structural, motility, or immune defects that allow colonic-type bacteria to colonize the small bowel. Identifying the underlying cause is as important as treating the overgrowth itself, because without addressing the root driver, recurrence is near-certain.

Impaired motility. The migrating motor complex (MMC), a cyclical pattern of intestinal contractions during fasting, normally sweeps bacteria distally toward the colon every 90 to 120 minutes. Conditions that disrupt the MMC predispose patients to SIBO. These include diabetic gastroparesis, scleroderma, hypothyroidism, opioid use, and post-infectious dysmotility 6. A 2019 study in Neurogastroenterology and Motility found that 43% of patients with diabetic neuropathy had positive glucose hydrogen breath tests 7.

Anatomical disruption. Surgical alterations to the GI tract create stagnant loops or remove the ileocecal valve, the physical barrier between the colon and small intestine. Roux-en-Y gastric bypass, small bowel resection, and Billroth II gastrectomy all carry elevated SIBO risk. Strictures from Crohn's disease produce similar stasis 8.

Acid suppression. Gastric acid kills swallowed and ingested bacteria before they reach the small intestine. Proton pump inhibitor (PPI) use, particularly at high doses for prolonged periods, is one of the most common modifiable risk factors. A meta-analysis by Su et al. (2018) in the Journal of Gastroenterology found PPI use increased SIBO risk with an odds ratio of 1.71 (95% CI 1.20 to 2.43) 9.

Immune deficiency. Secretory IgA deficiency, common variable immunodeficiency, and HIV/AIDS reduce the gut's ability to control bacterial populations. Patients on chronic immunosuppressive therapy may also be at increased risk 10.

Other associations. Chronic pancreatitis with exocrine insufficiency, celiac disease, liver cirrhosis, and chronic kidney disease have all been linked to elevated SIBO prevalence in cohort studies 11.

How SIBO Is Diagnosed

Diagnosis of SIBO relies on two categories of testing: breath testing (noninvasive, widely available) and small bowel aspirate culture (invasive, considered the reference standard). Each method has meaningful limitations.

Breath testing. The patient ingests a substrate (glucose or lactulose) after an overnight fast, then breathes into a collection device at timed intervals over 90 to 180 minutes. Bacterial fermentation of the substrate produces hydrogen, methane, or both, which are absorbed into the bloodstream and exhaled. A rise in hydrogen of 20 parts per million (ppm) or more above baseline within 90 minutes on the glucose breath test, or a methane level of 10 ppm or more at any point, is considered positive according to the 2017 North American Consensus by Rezaie et al. 4.

The glucose hydrogen breath test has reported sensitivity of 54% to 68% and specificity of 83% to 86% when measured against jejunal aspirate 12. Lactulose breath testing has higher sensitivity but significantly lower specificity, leading to more false positives. Neither test detects hydrogen sulfide with standard equipment. A trio-smart breath test measuring all three gases became available commercially in 2021, though peer-reviewed validation data remain limited.

Small bowel aspirate. An upper endoscopy with aspiration of jejunal fluid and quantitative culture remains the gold standard. A count of 10³ CFU/mL or greater is now diagnostic per the ACG guideline 1. This method is expensive, invasive, and subject to contamination from oropharyngeal flora during scope passage, which limits its use to refractory or diagnostically uncertain cases.

"Breath testing is the pragmatic first-line diagnostic for SIBO, but clinicians should interpret results in clinical context rather than treating the number alone," stated the ACG guideline panel in their 2020 publication 1.

Preparation matters. A preparatory diet of white rice, plain chicken or fish, and water for 24 hours before the test reduces baseline fermentation and improves accuracy. Patients should avoid antibiotics for four weeks and prokinetics for three days prior to testing.

SIBO vs. IBS: Understanding the Overlap

The relationship between SIBO and IBS has generated significant debate. Studies using breath testing report SIBO prevalence in IBS patients ranging from 4% to 78%, a range so wide it reflects differences in testing methodology more than true biology 3. A 2010 meta-analysis by Ford et al. in the American Journal of Gastroenterology found that IBS patients were 3.7 times more likely to have an abnormal breath test than healthy controls (OR 3.7 to 95% CI 2.3 to 5.9) 13.

The practical distinction: IBS is a symptom-based diagnosis defined by the Rome IV criteria (recurrent abdominal pain at least one day per week for three months, associated with defecation, a change in stool frequency, or a change in stool form). SIBO is a microbiological diagnosis. A patient can have both simultaneously. Treating SIBO in an IBS patient may reduce symptoms, but it does not necessarily resolve the underlying motility or visceral hypersensitivity driving the IBS phenotype 14.

The landmark TARGET 3 trial (N=2,579) demonstrated that rifaximin 550 mg TID for 14 days produced a 9% absolute benefit over placebo in IBS-D patients without requiring breath testing, suggesting bacterial overgrowth may contribute to symptoms even when breath tests are negative 15.

Clinicians should consider SIBO testing in IBS patients who have identifiable risk factors (PPI use, prior surgery, diabetes), who fail standard IBS therapies (low-FODMAP diet, antispasmodics), or who demonstrate signs of malabsorption such as vitamin deficiencies or steatorrhea.

Evidence-Based Treatment for SIBO

Treatment for SIBO targets three goals: eradicate the overgrowth, correct nutritional deficiencies, and address the underlying cause to reduce recurrence.

Antibiotics

Rifaximin is the best-studied antibiotic for hydrogen-dominant SIBO. It is poorly absorbed (less than 0.4% systemic bioavailability), concentrates in the gut lumen, and has a favorable side-effect profile 15. The standard regimen is 550 mg three times daily for 14 days. Breath test normalization rates range from 50% to 70% after a single course. A second 14-day course may be given if symptoms persist.

Methane-dominant overgrowth (IMO) responds poorly to rifaximin alone. The combination of rifaximin 550 mg TID plus neomycin 500 mg BID for 14 days produced a significantly higher methane eradication rate (85%) than rifaximin monotherapy (33%) in a 2014 study by Pimentel et al. in Digestive Diseases and Sciences 16. Metronidazole 250 mg TID for 14 days is an alternative to neomycin, though GI side effects are more common.

For patients who cannot access rifaximin (which costs approximately $1,800 per course without insurance), alternative systemic antibiotics include amoxicillin-clavulanate, ciprofloxacin, or doxycycline for 7 to 14 days. Evidence quality for these alternatives is lower 1.

Dietary Approaches

A low-FODMAP diet reduces the substrate available for bacterial fermentation and can improve symptoms during and after antibiotic therapy. A 2016 randomized trial by Halmos et al. showed that low-FODMAP intake reduced hydrogen breath production by 70% compared with a typical Australian diet in IBS patients 17. Clinicians typically recommend the elimination phase for 2 to 6 weeks, followed by systematic reintroduction to identify individual trigger foods.

The elemental diet (a liquid formula of predigested nutrients absorbed in the proximal small intestine, leaving nothing for bacteria to ferment) achieved an 85% breath test normalization rate at 14 days in a 2004 open-label study by Pimentel et al. 18. Its main limitations are poor palatability and cost.

Prokinetic Therapy

Because impaired motility drives recurrence, prokinetic agents are used after antibiotic treatment to restore normal MMC cycling. Low-dose erythromycin (50 to 100 mg at bedtime) acts as a motilin receptor agonist and has shown benefit in maintaining SIBO remission in small studies 6. Prucalopride (1 to 2 mg daily), a selective 5-HT4 agonist, is another option, particularly for patients with constipation-predominant symptoms. Low-dose naltrexone (4.5 mg at bedtime) is used off-label by some practitioners, though controlled trial data for SIBO prevention are lacking.

Nutritional Repletion

Patients with documented deficiencies should receive targeted supplementation: vitamin B12 (1 to 000 mcg sublingual or intramuscular), iron, vitamin D (2,000 to 5 to 000 IU daily), and fat-soluble vitamins as indicated by lab values. Medium-chain triglyceride (MCT) oil can be used as a caloric supplement in patients with significant fat malabsorption, since MCTs are absorbed without bile salt emulsification.

When to See a Doctor About SIBO-Like Symptoms

Not every episode of bloating warrants a breath test. Seek evaluation when bloating is daily and persistent for more than four weeks, when it is accompanied by unintentional weight loss (5% or more of body weight over 6 to 12 months), when stool changes include visible fat or oil, or when symptoms emerge after abdominal surgery or alongside a known motility disorder.

Red-flag symptoms that require prompt evaluation include rectal bleeding, progressive dysphagia, iron-deficiency anemia in men or postmenopausal women, and new-onset symptoms after age 50 19. These warrant endoscopic evaluation to exclude structural pathology before attributing symptoms to SIBO.

Preventing SIBO Recurrence

Recurrence is common. A 2018 retrospective analysis reported that approximately 45% of patients who achieved breath test normalization relapsed within 9 months 20. The highest recurrence rates occurred in patients with persistent risk factors: ongoing PPI use, uncontrolled diabetes, and surgical anatomy changes.

Strategies to reduce relapse:

• Discontinue unnecessary PPIs. If acid suppression is medically required, use the lowest effective dose. H2 receptor antagonists carry a lower SIBO risk than PPIs.
• Use prokinetic therapy. A nighttime prokinetic for 3 to 6 months post-treatment helps maintain MMC function.
• Optimize glycemic control. In diabetic patients, improving hemoglobin A1c reduces gastroparesis severity and supports normal intestinal motility.
• Space meals. Allowing 4 to 5 hours between meals and avoiding late-night eating gives the MMC adequate fasting time to perform its "housekeeping" sweeps.
• Limit unnecessary antibiotic courses. Repeated broad-spectrum antibiotics can paradoxically worsen dysbiosis.

Clinicians monitoring for recurrence typically repeat breath testing 4 to 6 weeks after completing antibiotics, then at 3-month and 6-month intervals if symptoms re-emerge. An empiric re-treatment approach (repeating rifaximin without re-testing) is reasonable in patients with clearly recurrent, pattern-consistent symptoms and a prior positive breath test.